Pharmabiz

Hyloris announces positive phase 1 data for HY-004, a proprietary tranexamic acid oral mouth rinse for bleeding related to dental procedures

Hyloris Pharmaceuticals SA, a specialty biopharma company, announced positive results from a phase 1 study of HY-004, an antifibrinolytic agent, tranexamic acid, as an oral mouth rinse proprietary ...
Healio

Tranexamic acid use may not increase thrombotic events in high-risk patients

Please provide your email address to receive an email when new articles are posted on . Tranexamic acid utilization did not increase the risk for thrombotic events in high-risk patients. Tranexamic ...
Medscape

Fatal Mix-Ups Spur EMA Warning on Tranexamic Acid Use

Fatal mix-ups between tranexamic acid and spinal anesthetics have prompted a strong safety warning by the European Medicines Agency (EMA), urging healthcare professionals to ensure the drug is ...
WDAF-TV

Hyloris Reports Positive Phase 1 Data for HY-004, a proprietary Tranexamic Acid Oral Mouth Rinse for bleeding related to dental procedures

HY-004 provides a new treatment alternative for use in patients on anti-coagulant therapies undergoing dental procedures that have a risk of bleeding or complication HY-004 administered locally had ...